Literature DB >> 17245025

Too much bone: the middle ear in sclerosing bone dysplasias.

Herman Hamersma1, Louis Hofmeyr.   

Abstract

The middle ear changes in Sclerosteosis and Van Buchem disease are described. Reduced bone resorption occurs due to faulty activity of the sclerostin molecule, a product of the recently discovered SOST gene in chromosome 17. Syndactyly draws attention to scleroteosis, and a conductive hearing loss develops before age six in both conditions. Acute, repeated attacks of facial palsy, similar to Bell's palsy, are usually the first symptoms in both conditions. Total facial nerve decompression can stop the attacks of facial paralysis. The hearing loss is a problem because new bone formation continues up to age 21. Life saving craniectomy becomes necessary when increased intracranial pressure develops, and this may have to repeated. The sclerostin molecule is now of major interest to the researchers who want to develop a treatment for osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17245025     DOI: 10.1159/000098673

Source DB:  PubMed          Journal:  Adv Otorhinolaryngol        ISSN: 0065-3071


  3 in total

1.  High-bone-mass-producing mutations in the Wnt signaling pathway result in distinct skeletal phenotypes.

Authors:  Paul J Niziolek; Takeisha L Farmer; Yajun Cui; Charles H Turner; Matthew L Warman; Alexander G Robling
Journal:  Bone       Date:  2011-08-09       Impact factor: 4.398

Review 2.  Perspectives of pharmacological treatment in otosclerosis.

Authors:  Balázs Liktor; Zoltán Szekanecz; Tamás József Batta; István Sziklai; Tamás Karosi
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-07-29       Impact factor: 2.503

3.  Recombinant sclerostin inhibits bone formation in vitro and in a mouse model of sclerosteosis.

Authors:  Timothy Dreyer; Mittal Shah; Carl Doyle; Kevin Greenslade; Mark Penney; Paul Creeke; Apoorva Kotian; Hua Zhu Ke; Vinny Naidoo; Gill Holdsworth
Journal:  J Orthop Translat       Date:  2021-06-21       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.